Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3373560 | 0.86 | LTB4R2 (0.46) | LTB4R2EPHX2HPGDALDH1A1POLB | |
| SCHEMBL5489422 | 0.84 | LTB4R2 (0.42) | LTB4R2HPGDALDH1A1HDAC1HDAC6 | |
| SCHEMBL9421652 | 0.84 | AOC3 (0.43) | LTB4R2HPGDALDH1A1HDAC8CNR1 | |
| SCHEMBL9787236 | 0.84 | EPHX2 (0.56) | LTB4R2EPHX2HPGDALDH1A1FAAH | |
| SCHEMBL9709753 | 0.82 | LTB4R2 (0.42) | LTB4R2 | |
| SCHEMBL5592312 | 0.81 | LTB4R2 (0.45) | LTB4R2 | |
| SCHEMBL8473823 | 0.80 | LTB4R2 (0.63) | LTB4R2 | |
| SCHEMBL3116176 | 0.80 | LTB4R2 (0.47) | LTB4R2HPGDALDH1A1HDAC3HDAC4 | |
| SCHEMBL7575469 | 0.80 | BDKRB1 (0.44) | LTB4R2HTTBDKRB1 | |
| SCHEMBL8081241 | 0.80 | BDKRB1 (0.44) | LTB4R2BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8981109-B2 | Process for the preparation of valsartan | AUROBINDO PHARMA LTD (IN) | 2015-03-17 | — | — | US | disclosed |
| US-8981109-B2 | Process for the preparation of valsartan | AUROBINDO PHARMA LTD (IN) | 2015-03-17 | — | — | US | disclosed |
| US-20130144067-A1 | PROCESS FOR THE PREPARATION OF VALSARTAN | AUROBINDO PHARMA LTD (IN) | 2013-06-06 | — | — | US | disclosed |
| US-20130144067-A1 | PROCESS FOR THE PREPARATION OF VALSARTAN | AUROBINDO PHARMA LTD (IN) | 2013-06-06 | — | — | US | disclosed |
| US-20120009637-A1 | Nitrilases, Nucleic Acids Encoding Them and Methods For Making and Using Them | VERENIUM CORPORATION (US) | 2012-01-12 | — | — | US | disclosed |
| US-7993901-B2 | Nitrilases and methods for making and using them | VERENIUM CORPORATION (US) | 2011-08-09 | — | — | US | disclosed |
| EP-2327767-A1 | Nitrilases | Verenium Corporation (US) | 2011-06-01 | — | — | EP | disclosed |
| EP-2327766-A1 | Nitrilases | Verenium Corporation (US) | 2011-06-01 | — | — | EP | disclosed |
| EP-2319919-A1 | Nitrilases | Verenium Corporation (US) | 2011-05-11 | — | — | EP | disclosed |
| US-20100273659-A1 | Nitrilases, Nucleic Acids Encoding Them and Methods for Making and Using Them | VERENIUM CORPORATION (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100216214-A1 | hydrolysis of a hydroxyglutaryl nitrile to generate an ethyl 4-cyano-3-hydroxybutyrate; hydrolysis of a mandelonitrile to generate a mandelic acid; hydrolysis of phenyllactocyanonitrile to generate an (S)-phenyllactic acid | VERENIUM CORPORATION (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100086986-A1 | Increased activity and stability at increased pH and temperature; making a chiral alpha -hydroxy acid molecule, a chiral amino acid molecule, a chiral beta -hydroxy acid molecule, or a chiral gamma-hydroxy acid molecule, from a molecule with a cyanohydrin moiety or an aminonitrile moiety | VERENIUM CORPORATION (US) | 2010-04-08 | — | — | US | disclosed |
| US-7608445-B1 | Nitrilases, nucleic acids encoding them and methods for making and using them | VERENIUM CORPORATION (US) | 2009-10-27 | — | — | US | disclosed |
| EP-2039762-A2 | Nitralases | Verenium Corporation (US) | 2009-03-25 | — | — | EP | disclosed |
| EP-1910251-A1 | METHOD FOR ISOLATING 5-SUBSTITUTED TETRAZOLES | Sanochemia Pharmazeutika Aktiengesellschaft (AT) | 2008-04-16 | — | — | EP | disclosed |
| US-7199144-B2 | Process for the preparation of valsartan and intermediates thereof | TEVA PHARMACEUTICALS INDUSTRIES, LTD. (IL) | 2007-04-03 | — | — | US | disclosed |
| WO-2007014412-A1 | METHOD FOR ISOLATING 5-SUBSTITUTED TETRAZOLES | SANOCHEMIA PHARMAZEUTIKA AG (AT) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100086986-A1 | Increased activity and stability at increased pH and temperature; making a chiral alpha -hydroxy acid molecule, a chiral amino acid molecule, a chiral beta -hydroxy acid molecule, or a chiral gamma-hydroxy acid molecule, from a molecule with a cyanohydrin moiety or an aminonitrile moiety | ASPH, AHSA1, DNPH1 | LTB4R2 4046/4885EPHX2 1380/4885HPGD 226/4885 |
| US-20130144067-A1 | PROCESS FOR THE PREPARATION OF VALSARTAN | TTR, VIP, VIL1 | LTB4R2 189/4885EPHX2 3350/4885HPGD 1073/4885 |
| US-20120009637-A1 | Nitrilases, Nucleic Acids Encoding Them and Methods For Making and Using Them | RNGTT, NSUN2, NSUN3 | LTB4R2 4564/4885EPHX2 3521/4885HPGD 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.